Agilent Wins FDA Approval for PD-L1 22C3 Test
Santa Clara, USA – March 26, 2026 Agilent Technologies announced U.S. FDA approval of its PD-L1 IHC 22C3 pharmDx...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Santa Clara, USA – March 26, 2026 Agilent Technologies announced U.S. FDA approval of its PD-L1 IHC 22C3 pharmDx...
FRIENDSWOOD, Texas, Feb. 19, 2026 — Castle Biosciences announced prospective clinical validation data published in the Journal of the...
SEOUL, South Korea — September 22, 2025 — Lunit and Agilent Technologies have launched a non-exclusive collaboration to co-develop...
